Compare Medpace Holdings Inc (MEDP) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Prospect Capital Corporation — how do they compare? Medpace Holdings Inc trades at $597.5 (market cap $16.90B), while Prospect Capital Corporation trades at $2.3 (market cap $1.14B). The key difference: Medpace Holdings Inc is far larger — about 14.8× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 21.93% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | PSEC | |
|---|---|---|
Market Cap | $16.90B | $1.14B |
Sector | Technology | Financials |
52-Week High | $620.59 | $3.05 |
52-Week Low | $393.42 | $2.11 |
Enterprise Value | $16.52B | — |
Dividend Yield | — | 21.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PSEC trades at $2.29, down 1.72% on the day, with a mixed technical picture showing a bullish moving average signal but neutral oscillators. The stock carries a low P/B of 0.39 and has beaten earnings estimates for three consecutive quarters, though it reported a net loss of $469.92 million in 2025. Recent news includes a dividend increase announcement and the sale of portfolio company Valley Electric for $328 million.
The outlook is cautious; while the deep discount to book value and consistent dividend payments offer income appeal, significant negative revenue and net income margins, alongside a divided analyst consensus, highlight substantial business and market risks. The primary opportunity lies in a potential valuation recovery if operational performance improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
